Evidence map›Paper›PMID 40987292›Full record

ArticleAmerican journal of human genetics2025

Heterozygous pathogenic variants in the splicing factor SF1 lead to a large spectrum of neurodevelopmental disorders.

Johnny Bou-Rouphael, Auriane Cospain, Thomas Courtin, Boris Keren, Corentine Marie, Marion Lesieur-Sebellin, Delphine Heron, Jean-Madeleine de Sainte Agathe, Solveig Heide, Elodie Lejeune and 35 more

Abstract read
In one paragraph

Article in American journal of human genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Neurodegenerative spliceosomopathies.Frontiers in cell and developmental biology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors.

Johnny Bou-RouphaelParis Brain Institute, Sorbonne Université, Inserm U1127, CNRS UMR 7225, Hôpital Pitié-Salpêtrière, 75013 Paris, France.
Auriane CospainParis Brain Institute, Sorbonne Université, Inserm U1127, CNRS UMR 7225, Hôpital Pitié-Salpêtrière, 75013 Paris, France.
Thomas CourtinDépartement de Génétique Médicale, Centre de référence déficience intellectuelle, APHP Sorbonne Université, Hôpitaux Pitié-Salpêtrière et Armand Trousseau, 75013 Paris, France.
Boris KerenDépartement de Génétique Médicale, APHP Sorbonne Université, Hôpital Pitié-Salpêtrière, 75013 Paris, France.
Corentine MarieParis Brain Institute, Sorbonne Université, Inserm U1127, CNRS UMR 7225, Hôpital Pitié-Salpêtrière, 75013 Paris, France.
Marion Lesieur-SebellinDépartement de Génétique Médicale, APHP Sorbonne Université, Hôpital Pitié-Salpêtrière, 75013 Paris, France.
Delphine HeronDépartement de Génétique Médicale, Centre de référence déficience intellectuelle, APHP Sorbonne Université, Hôpitaux Pitié-Salpêtrière et Armand Trousseau, 75013 Paris, France.
Jean-Madeleine de Sainte AgatheDépartement de Génétique Médicale, APHP Sorbonne Université, Hôpital Pitié-Salpêtrière, 75013 Paris, France.
Solveig HeideDépartement de Génétique Médicale, Centre de référence déficience intellectuelle, APHP Sorbonne Université, Hôpitaux Pitié-Salpêtrière et Armand Trousseau, 75013 Paris, France.
Elodie LejeuneDépartement de Génétique Médicale, APHP Sorbonne Université, Hôpital Pitié-Salpêtrière, 75013 Paris, France.
Chloe QuelinService de Génétique Clinique, Centre de Référence Maladies Rares CLAD-Ouest, CHU Rennes, 35000 Rennes, France.
François LecoquierreDépartement de Génétique et Centre de Référence Maladies Rares, Normandie University, UNIROUEN, Inserm U1245, FHU G4 Génomique, CHU Rouen, 76000 Rouen, France.
Mathilde NizonService de Génétique Médicale, CHU Nantes, 44093 Nantes, France.
Bertrand IsidorService de Génétique Médicale, CHU Nantes, 44093 Nantes, France.
Thomas BesnardService de Génétique Médicale, CHU Nantes, 44093 Nantes, France.
Benjamin CogneService de Génétique Médicale, CHU Nantes, 44093 Nantes, France.
Xenia LatypovaDépartement de Génétique, Hôpital Robert Debré, 75019 Paris, France.
Jonathan LevyDépartement de Génétique, Hôpital Robert Debré, 75019 Paris, France.
Pascal JosetInstitute of Medical Genetics, University of Zürich, 8952 Schlieren, Switzerland.
Katharina SteindlInstitute of Medical Genetics, University of Zürich, 8952 Schlieren, Switzerland.
Maria Palomares-BraloUnidad de Diagnóstico Molecular y Genética Clínica, Hospital Universitario Son Espases, IdISBa, 07120 Palma de Mallorca, Spain.
Fernando Santos-SimarroUnidad de Diagnóstico Molecular y Genética Clínica, Hospital Universitario Son Espases, IdISBa, 07120 Palma de Mallorca, Spain.
Mary Ann ThomasDepartments of Medical Genetics and Pediatrics, Cumming School of Medicine, Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada.
Amina AbubakarCenter for Geographic Medicine Research Coast, Neuroscience Unit, KEMRI-Wellcome Trust, Kilifi, Kenya; Institute of Human Development, Aga Khan University, Nairobi, Kenya; Department of Psychiatry, University of Oxford, London, UK.
Sally Ann LynchDepartment of Clinical Genetics, Children's Health Ireland (CHI) at Crumlin, Dublin, Ireland.
Amelie J MüllerInstitute of Medical Genetics and Applied Genomics, University of Tübingen, 72074 Tübingen, Germany.
Tobias B HaackInstitute of Medical Genetics and Applied Genomics, University of Tübingen, 72074 Tübingen, Germany; Center for Rare Disease, Genomics for Health in Africa (GHA), Africa-Europe Cluster of Research Excellence (CoRE), University of Tübingen, 72074 Tübingen, Germany.
Martin ZenkerInstitute of Human Genetics, University Hospital, 39120 Magdeburg, Germany.
Michael ParkerGenetics Service, Sheffield Children's NHS Foundation Trust, Sheffield, UK.
Emma ClossickGenetics Service, Sheffield Children's NHS Foundation Trust, Sheffield, UK.
Michael SpillerGenetics Service, Sheffield Children's NHS Foundation Trust, Sheffield, UK.
Renarta CrookesGenetics Service, Sheffield Children's NHS Foundation Trust, Sheffield, UK.
Muriel Holder-EspinasseClinical Genetics Department, Guy's & St Thomas' NHS Foundation Trust, Guy's Hospital, London, UK.
Allan BayatDepartment of Child Neurology, Danish Epilepsy Centre, 4293 Dianalund, Denmark.
Rikke S MøllerDepartment of Epilepsy Genetics and Personalized Medicine, Danish Epilepsy Centre, 4293 Dianalund, Denmark; Department of Regional Health Research, University of Southern Denmark, 5230 Odense, Denmark.
Tomasz Stanislaw MieszczanekDepartment of Child Neurology, Danish Epilepsy Centre, 4293 Dianalund, Denmark.
Pierre de la GrangeGenoSplice, 75014 Paris, France.
Julien BurattiDépartement de Génétique Médicale, APHP Sorbonne Université, Hôpital Pitié-Salpêtrière, 75013 Paris, France.
Pierre MarijonLaboratoire de Médecine Génomique SeqOIA, 75014 Paris, France.
Sabir AtafWest Midlands Regional Clinical Genetics Service and Birmingham Health Partners, Birmingham Women's and Children's Hospitals NHS Foundation Trust, Birmingham, UK.
Ryan GavinWest Midlands Regional Clinical Genetics Service and Birmingham Health Partners, Birmingham Women's and Children's Hospitals NHS Foundation Trust, Birmingham, UK.
Carlos ParrasParis Brain Institute, Sorbonne Université, Inserm U1127, CNRS UMR 7225, Hôpital Pitié-Salpêtrière, 75013 Paris, France.
Bassem A HassanParis Brain Institute, Sorbonne Université, Inserm U1127, CNRS UMR 7225, Hôpital Pitié-Salpêtrière, 75013 Paris, France.
Cyril MignotDépartement de Génétique Médicale, Centre de référence déficience intellectuelle, APHP Sorbonne Université, Hôpitaux Pitié-Salpêtrière et Armand Trousseau, 75013 Paris, France.
Laïla El KhattabiParis Brain Institute, Sorbonne Université, Inserm U1127, CNRS UMR 7225, Hôpital Pitié-Salpêtrière, 75013 Paris, France; Département de Génétique Médicale, APHP Sorbonne Université, Hôpital Pitié-Salpêtrière, 75013 Paris, France. Electronic address: laila.elkhattabi@icm-institute.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alternative splicing is highly prevalent in the brain where it orchestrates key processes such as neurogenesis and synaptogenesis, both essential for the nervous system's complexity and plasticity. Dysregulation of splicing has increasingly been linked to neurodevelopmental disorders. Here, we describe unrelated individuals carrying de novo, likely deleterious heterozygous variants in Splicing Factor 1 (SF1), all presenting with neurodevelopmental disorders of variable severity, frequently accompanied by autistic traits and other non-specific features. SF1 is a core component of pre-mRNA processing, facilitating early spliceosome assembly at the 3' splice site and regulating alternative splicing. We conducted functional studies in neural progenitor cells, which showed that SF1 downregulation alters gene expression and alternative splicing programs, particularly in genes involved in neuronal differentiation, synaptic transmission, and axonal guidance, processes fundamental to brain development. Together, these findings establish SF1 dysfunction as an additional spliceosomopathy contributing to neurodevelopmental disorders and underscore its essential role in human neurodevelopment and disease.

Indexed as

Neurodevelopmental DisordersRNA Splicing FactorsAdolescentAdultAlternative SplicingChildChild, PreschoolFemaleHeterozygoteHumansMaleMutationNeural Stem CellsRNA Splicing Factorsbrain developmentgene regulationgenetic variantsintellectual deficiencyneurodevelopmentRNA processingSF1spliceosome assemblysplicing factor

Identifiers

PMID40987292
PMCPMC12808962

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.